US 12,419,811 B2
Hydrogel drug delivery composition
Dong Wang, Omaha, NE (US); Yosif Almoshari, Abha (SA); Rongguo Ren, Omaha, NE (US); and Ningrong Chen, Omaha, NE (US)
Assigned to BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, Lincoln, NE (US)
Appl. No. 17/604,659
Filed by Board of Regents of the University of Nebraska, Lincoln, NE (US)
PCT Filed Apr. 20, 2020, PCT No. PCT/CN2020/085549
§ 371(c)(1), (2) Date Oct. 18, 2021,
PCT Pub. No. WO2020/211859, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/835,542, filed on Apr. 18, 2019.
Prior Publication US 2022/0218571 A1, Jul. 14, 2022
Int. Cl. A61K 47/10 (2017.01); A61K 6/20 (2020.01); A61K 6/69 (2020.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61P 31/00 (2006.01)
CPC A61K 6/20 (2020.01) [A61K 6/69 (2020.01); A61K 9/0063 (2013.01); A61K 9/06 (2013.01); A61K 47/10 (2013.01); A61P 31/00 (2018.01)] 19 Claims
 
1. A drug delivery composition comprising a therapeutic agent and a mixture of a poloxamer and its corresponding pyrophosphorylated poloxamer,
wherein the poloxamer has the structure:

OG Complex Work Unit Chemistry
wherein x and z are 101 and y is 56;
wherein said pyrophosphorylated poloxamer has the structure:

OG Complex Work Unit Chemistry
wherein x and z are 101 and y is 56; and
wherein the drug delivery composition is a thermoresponsive hydrogel.